Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11
Yanjiao Zhu1, Yichuan Zhao1, Siyao Dong1
1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Abstract:
Aberrant expression of long non-coding RNAs (lncRNAs) leads to the development of chemoresistance by regulating a series of biological processes, which is one of the major obstacles in the cancer treatment. This study aimed to identify some key lncRNAs that are associated with platinum-based chemoresistance in multiple cancers. Regulating the expression levels of these lncRNAs can enhance the sensitivity of patients to chemotherapy drugs and improve the therapeutic effect of cancer. By systematically analyzing 648 samples regarding platinum drug response from the Cancer Genome Atlas (TCGA), we have identified 32 dysregulated lncRNAs across 11 cancer types that could affect platinum-based chemotherapy response, of which 78.125% (25/32) were significantly down-regulated in drug-resistant samples. Drug response prediction model that had been constructed based on the expression pattern of these dysregulated lncRNAs could accurately predict the chemotherapy response of tumor patients, and the area under the curve (AUC) was between 0.8034 and 0.9984. In particular, all of these dysregulated lncRNAs that we identified were cancer-specific. They were significantly associated with the survival of tumor patients and could serve as cancer-specific biomarkers for prognosis. In conclusion, this study will contribute to improving the drug resistance of tumor patients during chemotherapy, and it is of real significance for selecting effective chemotherapy drugs and achieving precision medicine.
Insights
This study identified 32 key long non-coding RNAs (lncRNAs) linked to platinum drug resistance in 11 cancers. Lowering lncRNA levels may improve chemotherapy effectiveness and patient survival.
Area of Science:
- Genomics
- Cancer Biology
- Molecular Oncology
Background:
- Aberrant expression of long non-coding RNAs (lncRNAs) contributes to chemoresistance, hindering cancer treatment efficacy.
- Identifying specific lncRNAs involved in chemoresistance is crucial for developing targeted therapeutic strategies.
Purpose of the Study:
- To identify key long non-coding RNAs (lncRNAs) associated with platinum-based chemoresistance across multiple cancer types.
- To evaluate the potential of these lncRNAs as biomarkers for predicting chemotherapy response and patient prognosis.
Main Methods:
- Systematic analysis of 648 platinum drug response samples from The Cancer Genome Atlas (TCGA).
- Identification and characterization of dysregulated lncRNAs in drug-resistant versus sensitive cancer samples.
- Development and validation of a drug response prediction model based on lncRNA expression patterns.
Main Results:
- Identified 32 dysregulated lncRNAs across 11 cancer types affecting platinum-based chemotherapy response.
- Found that 78.125% (25/32) of these lncRNAs were significantly down-regulated in drug-resistant samples.
- Developed a prediction model with high accuracy (AUC 0.8034–0.9984) for chemotherapy response.
- Confirmed that identified lncRNAs are cancer-specific, associated with patient survival, and serve as prognostic biomarkers.
Conclusions:
- Dysregulated lncRNAs play a significant role in platinum-based chemoresistance across various cancers.
- These identified lncRNAs can serve as cancer-specific biomarkers for prognosis and predicting chemotherapy response.
- Targeting these lncRNAs holds potential for improving patient sensitivity to chemotherapy and advancing precision medicine in oncology.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Types of Responses of Series RLC Circuits
Random and Systematic Errors
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Propagation of Uncertainty from Systematic Error
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Classification of Titrimetric Analysis Based on Reaction Types
Titrations between an acid and a base lead to neutralization reactions that form...